A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
A legfontosabb adatok
- Ki végzi
- Codagenix, Inc
- Hol
- Boston és Canton (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 1. fázis
- Kezdés
- 2023. jan. 15.
- Befejezés
- 2025. jan. 30.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoport
- A vizsgált kezelések
- CodaLytic
- A regiszteradat frissítve
- 2023. október 18.
- Miért állt le
- Due to funding decision by the sponsor
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Women or men with metastatic or inoperable, histologically confirmed breast cancer
- Has no alternative treatment of proven benefit available or has refused treatment
- Expected survival ≥ 3 months
- At least 2 measurable lesions according to RECIST 1.1, without contraindication for repeated injections and core needle biopsies
- Adequate organ function
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Negative pregnancy test, if female
- Agreement to practice a highly effective method of contraception
- Agreement to no sperm donation through 28 days, if male
- Willing to provide consent to perform study procedures
Ki nem vehet részt
- Anticancer therapy within 3 weeks of dosing
- Presence of a concurrent malignancy for which the natural history or treatment has the potential to interfere with the safety or efficacy assessment of the Investigational Product
- Immunodeficiency or use of therapies expected to impair the immune response within thirty (30) days of enrollment or during dosing
- Ongoing toxicity > Grade 1 from prior treatment except those which are stable
- Planned radiation to lesions targeted for assessment/injection within 60 days before first dose or any planned radiation during dosing period
- Uncontrolled or severe cardiovascular disease
- History of severe reaction (ie, anaphylaxis) to vaccination or immunotherapy
- Any condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety, or a participant's ability to give informed consent
- Pregnant or lactating women
- Known active central nervous system metastases (with some exceptions)
Helyszínek itt: Egyesült Államok
- Dana-Farber Cancer InstituteBoston, Egyesült Államok
- Gabrail Cancer CenterCanton, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast cancer.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* How safe is CodaLytic when administered in escalating dosing groups into targeted lesions? * What is the impact of CodaLytic on lesion response and disease progression?
Eligible participants will be enrolled into four (4) escalating dose groups and treated with Codalytic through injection into a selected lesion(s) over twelve (12) weeks and then followed for up to one (1) year after the first dose. A safety committee will review the safety profile of each dosing group before the next dose-escalation.
Study procedures will include physical examinations, injection site assessments, biopsies, imaging, and collection of blood/urine to assess safety, the body's immune response, and efficacy.
A vizsgálat 4 csoportja
- 10e7 PFU dose 3 injectionsA vizsgált kezelés
10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
Kezelés: CodaLytic
- 10e7 PFU dose 5 injectionsA vizsgált kezelés
10e7 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
Kezelés: CodaLytic
- 10e8 PFU dose 3 injectionsA vizsgált kezelés
10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
Kezelés: CodaLytic
- 10e8 PFU dose 5 injectionsA vizsgált kezelés
10e8 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
Kezelés: CodaLytic
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer
- A regiszteradat frissítve
- 2023. október 18.